|
|
News Breaks | | | | October 10, 2012 | | 07:08 EDT |  | ACOR | Acorda Therapeutics presents two-year safety data for AMPYRA
Acorda Therapeutics announced safety data from more than 62,400 people with multiple sclerosis taking AMPYRA (dalfampridine) Extended Release Tablets, 10 mg during the first two years of availability in the U.S: The data showed that the safety profile of AMPYRA is similar to that observed in clinical trials. 160 seizures were reported, or approximately 4.6 per 1000 patient-years of use. This rate is comparable to the rate of seizure seen in the overall MS population. The most frequently reported AEs were dizziness, insomnia, balance disorder, headache, nausea, urinary tract infection, back pain, and asthenia. These are similar to the AEs most frequently reported during AMPYRA clinical trials. | |
|
News For ACOR From The Last 14 Days Check below for free stories on ACOR the last two weeks. |
|
|
| May 20, 2013 | | 07:12 EDT | | ACOR | Acorda Therapeutics says issued additional U.S. patent for AMPYRA
 Subscribe for More Information | | | May 9, 2013 | | 10:11 EDT |  | ACOR | Acorda Therapeutics has a conference call hosted by JPMorgan
Subscribe for More Information | | | 07:05 EDT | | ACOR | Acorda says data support initiation of current dalfampridine development program
Subscribe for More Information | |
|
|
|
|
|
|
